Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Discovery of Novel EPO/EPOR/JAK2 Targets and Signal Transduction Factors Via Proteomic-Based Interrogations of Post-Translational Motif Modifications

Don M Wojchowski, PhD, Su Su, PhD, Ashley Johnson, BA, Edward Jachimowicz, MS, Matthew P Stokes, PhD, Jennifer M Green, PhD, Jeffrey C Silva, PhD

Blood (2014) 124 (21): 1335.

https://doi.org/10.1182/blood.V124.21.1335.1335

Published: 2014

Journal Articles

Ligand-Regulated and Developmental Stage-Specific Expression Of The EPO Receptor During Human Erythroid Progenitor Cell Formation

Nicole Rainville, David Kuhrt, PhD, Su Su, PhD, Edward Jachimowicz, MS, Asch Ruth, Lei Li, MD PhD, Jennifer M Green, PhD, Don M. Wojchowski, PhD

Blood (2013) 122 (21): 3424.

https://doi.org/10.1182/blood.V122.21.3424.3424

Published: 2013

Journal Articles

Transcriptome- Based Analysis of EPO Dependent Cfu-e to Erythroblast Development

Rakesh Verma, Ph.D, Aishwarya Narayanan, PhD, David Kuhrt, PhD, Lei Li, PhD, Su Su, PhD, Ruth Asch, BA, Edward Jachimowicz, MS, Don M. Wojchowski, PhD

Blood (2012) 120 (21): 3188.

https://doi.org/10.1182/blood.V120.21.3188.3188

Published: 2012

Journal Articles

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Aleah Smith, BS, Maria Berg, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1786.

https://doi.org/10.1182/blood.V110.11.1786.1786

Published: 2007

Journal Articles

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Maria Berg, BS, Aleah Smith, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1789.

https://doi.org/10.1182/blood.V110.11.1789.1789

Published: 2007

NARROW

Discovery of Novel EPO/EPOR/JAK2 Targets and Signal Transduction Factors Via Proteomic-Based Interrogations of Post-Translational Motif Modifications

Ligand-Regulated and Developmental Stage-Specific Expression Of The EPO Receptor During Human Erythroid Progenitor Cell Formation

Transcriptome- Based Analysis of EPO Dependent Cfu-e to Erythroblast Development

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Email alerts

ASH Publications

American Society of Hematology

Discovery of Novel EPO/EPOR/JAK2 Targets and Signal Transduction Factors Via Proteomic-Based Interrogations of Post-Translational Motif Modifications

Ligand-Regulated and Developmental Stage-Specific Expression Of The EPO Receptor During Human Erythroid Progenitor Cell Formation

Transcriptome- Based Analysis of EPO Dependent Cfu-e to Erythroblast Development

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only